NYSE:PEN
Penumbra Inc Stock News
$203.53
+2.00 (+0.99%)
At Close: May 17, 2024
Penumbra (PEN) Q4 Earnings Top Estimates, Sales Remain Robust
01:42pm, Friday, 24'th Feb 2023 Zacks Investment Research
Penumbra's (PEN) sales during the fourth quarter reflect continued demand for its products. The 2023 outlook is encouraging as EPS improves despite macro challenges.
Expert Ratings for Penumbra
12:00pm, Friday, 24'th Feb 2023 Benzinga
Penumbra (NYSE:PEN) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
6
3
0
0
0
Last 30D
1
0
0
Penumbra (PEN) Q4 Earnings Top Estimates, Sales Remain Robust
09:47am, Friday, 24'th Feb 2023
Penumbra's (PEN) sales during the fourth quarter reflect continued demand for its products. The 2023 outlook is encouraging as EPS improves despite macro challenges.
Penumbra (PEN) Q4 Earnings and Revenues Surpass Estimates
11:30pm, Thursday, 23'rd Feb 2023 Zacks Investment Research
Penumbra (PEN) delivered earnings and revenue surprises of 14.29% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Q4 Earnings and Revenues Surpass Estimates
07:34pm, Thursday, 23'rd Feb 2023
Penumbra (PEN) delivered earnings and revenue surprises of 14.29% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?
04:51pm, Wednesday, 22'nd Feb 2023 Zacks Investment Research
DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong performance in the Technologies & Equipment business.
Should You Buy Penumbra (PEN) Ahead of Earnings?
01:42pm, Wednesday, 22'nd Feb 2023 Zacks Investment Research
Penumbra (PEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Buy Penumbra (PEN) Ahead of Earnings?
09:47am, Wednesday, 22'nd Feb 2023
Penumbra (PEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
03:00pm, Monday, 20'th Feb 2023 Zacks Investment Research
Si-Bone (SIBN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
01:06pm, Monday, 20'th Feb 2023 Zacks Investment Research
High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) fourth-quarter top line.
Penumbra (PEN) Earnings Expected to Grow: Should You Buy?
03:01pm, Thursday, 16'th Feb 2023 Zacks Investment Research
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Stock Picks for Week of February 13, 2023
09:14pm, Monday, 13'th Feb 2023 Zacks Investment Research
A Medical and Financial Stock Worth a Look.
AMN Healthcare (AMN) to Post Q4 Earnings: What's in the Cards?
02:27pm, Monday, 13'th Feb 2023 Zacks Investment Research
AMN Healthcare's (AMN) fourth-quarter results are likely to reflect soft demand across the majority of its segments.
What's in Store for West Pharmaceutical (WST) in Q4 Earnings?
02:11pm, Monday, 13'th Feb 2023 Zacks Investment Research
West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and the botto
